teclistamab,daratumumab,talquetamab
genmab,janssen
['mmsm', 'talquetamab', 'redirectt-1', 'teclistamab']
aa4/redirectt-1 study with teclistamab + talquetamab in rrmm (t-squared), (i will focus on the targeted dose)
- rrmm lot: 4 - emd: 32%
- high-risk cyto: 33%
- triple class rrmm: 77%
- bcma exposed:15% #mmsm #myeloma #medtiwtter #usmirc #asco23 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter